Enovix

ENVX · NASDAQ

$2.25−$0.10 (−4.26%)TodayMarket closed ·
Prev close $2.35

ENVX analyst rating

BuyConsensus of 10 analysts over the last 12 months. 60% rate it a buy.
  • Strong buy0
  • Buy6
  • Hold3
  • Underperform1
  • Sell0

12-month price target · 12 analysts

Average $11.58 (+414.5% upside)

Low
$5.05
Now
$2.25
High
$22.05

Upgrades and downgrades

The latest rating actions, newest first

ENVX analyst upgrades, downgrades and rating actions
FirmDateActionRating
StoneXOct 9, 2026MaintainsBuy
William BlairAug 17, 2026DowngradeOutperform → Market Perform
Canaccord GenuityAug 14, 2026MaintainsBuy
B. Riley SecuritiesAug 13, 2026MaintainsBuy
Cantor FitzgeraldAug 13, 2026MaintainsOverweight
TD CowenJul 24, 2026MaintainsHold
OppenheimerMay 14, 2026MaintainsOutperform
Craig-HallumMay 14, 2026MaintainsBuy
TD CowenMay 14, 2026MaintainsHold
BenchmarkMay 14, 2026MaintainsBuy

The case for and against

Updated Oct 17, 2026

Bull case

Enovix is attractive fundamentally because its 3D lithium-ion architecture with a 100% active silicon anode appears differentiated, hard to replicate, and already showing commercial traction through a 24% to 133% battery-performance improvement claim, supporting a credible long-term share gain in a $60B+ market. Near-term execution is improving as the lead smartphone customer cleared more than 1,000 cycles and is in the final accelerated qualification test expected in 4Q26, while smart eyewear has moved to revenue with about 2,100 batteries shipped and roughly 19,000 packs ordered for 3Q26. Financially, the business is still loss-making with Q3 forecast at $9.5M revenue, a $30.4M non-GAAP operating loss, and ($0.14) adjusted EPS, but the pipeline grew to $183M and Korea capacity expansion expected in mid-2027 should drive scale and margin leverage.

Bear case

Enovix is viewed negatively because its commercialization ramp remains slow, with only $38.9M of revenue expected in 2026 and $78.7M in 2027, while adjusted EBITDA losses stay wide at $81.7M and $89.1M. The company also faces substantial execution risk, as its unproven battery architecture has yet to demonstrate reliable mass production, and management says smart eyewear will remain dilutive through 2026 until volumes scale. Liquidity is another concern: cumulative free cash flow outflows of about $402.3M through 2028, a $172.5M convertible-note maturity, and only $42.8M of unrestricted cash and investments at year-end 2028 suggest financing needs, dilution risk, and constrained flexibility.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.